Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial

By sjmartinez • October 19, 2023

Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial. EClinicalMedicine. 2023 Oct 6;65:102250. doi: 10.1016/j.eclinm.2023.102250. PMID: 37855026; PMCID: PMC10579289.

Tags: ACTIV-2, covid-19, Infectious Diseases, Inhaled interferon, Publications, Randomized clinical trial, SARS-CoV-2

Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial

Vyshenska D, Reed JC, Roychoudhury P, Zheng L, Olefsky M, Ritz J, McCarthy C, Saha PT, Hao L, Mills MG, Shea A, Nunley BE, Javan[...]

Advancing the inclusion of pregnant and lactating populations in HIV PrEP research: ethical, regulatory, and surveillance recommendations from a multisectoral working group

Osakwe CE, Schaefer R, Donaldson L, Abiodun AS, Chatani-Gada M, Chigome AK, Day S, Deaton C, Elemuwa UG, Ingold H, Joseph Davey D, Kersey K,[...]

A Community-Based Intervention to Increase PrEP Initiation and Reduce Internalized Stigma: A Randomized Trial Among Black Sexual Minority Men in Prince George’s County, Maryland

Turpin RE, Wilson GT, Davidson Mhonde RR, Camp AD, Dyer TV, Mayer KH, Liu H, Coates T, Boekeloo B. A Community-Based Intervention to Increase PrEP[...]